Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Vertex Pharmaceuticals    VRTX

VERTEX PHARMACEUTICALS

(VRTX)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/15/2019 08/16/2019 08/19/2019 08/20/2019 08/21/2019 Date
181.12(c) 184.94(c) 187.09(c) 183.72(c) 185.43 Last
829 130 1 331 099 963 229 1 001 309 340 026 Volume
+0.89% +2.11% +1.16% -1.80% +0.93% Change
More quotes
Financials (USD)
Sales 2019 3 700 M
EBIT 2019 1 554 M
Net income 2019 870 M
Finance 2019 3 443 M
Yield 2019 -
Sales 2020 4 506 M
EBIT 2020 2 138 M
Net income 2020 1 208 M
Finance 2020 4 640 M
Yield 2020 -
P/E ratio 2019 54,6x
P/E ratio 2020 38,9x
EV / Sales2019 11,8x
EV / Sales2020 9,45x
Capitalization 47 223 M
More Financials
Company
Vertex Pharmaceuticals specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales break down by type of income as follows: - income from sales of products (99.7%); - royalties and... 
More about the company
Surperformance© ratings of Vertex Pharmaceuticals
Trading Rating : Investor Rating :
More Ratings
Latest news on VERTEX PHARMACEUTICALS
08:24aVERTEX PHARMACEUTICALS : FDA Accepts New Drug Application for VX-445, Tezacaftor..
AQ
08/20VERTEX PHARMACEUTICALS : FDA Accepts New Drug Application for VX-445 (Elexacafto..
BU
08/01VERTEX PHARMACEUTICALS : MA Management's Discussion and Analysis of Financial Co..
AQ
07/31VERTEX : 2Q Earnings Snapshot
AQ
07/31VERTEX PHARMACEUTICALS INC / MA : Results of Operations and Financial Condition,..
AQ
07/31VERTEX PHARMACEUTICALS : Reports Second-Quarter 2019 Financial Results
BU
07/25VERTEX PHARMACEUTICALS INC / MA : Change in Directors or Principal Officers, Fin..
AQ
07/25VERTEX PHARMACEUTICALS : Announces Dr. Jeffrey Leiden to Transition to Role of E..
BU
07/22VERTEX PHARMACEUTICALS : Submits New Drug Application to the U.S. FDA for Triple..
BU
07/17VERTEX PHARMACEUTICALS : to Announce Second-Quarter 2019 Financial Results on Ju..
BU
More news
Analyst Recommendations on VERTEX PHARMACEUTICALS
More recommendations
Sector news : Bio Therapeutic Drugs
08/15European Medicines Agency Reviews Arthritis Treatment by Gilead, Galapagos
DJ
08/12REGENERON PHARMACEUTICALS : Two Experimental Ebola Drugs Reduce Mortality Rate
DJ
08/08Sarepta says adverse event report for DMD gene therapy erroneously submitted
RE
08/08AGENUS : FDA Accepts AGEN2373 IND, Triggering $7.5 Million Milestone
DJ
08/07NOVARTIS : Medicare Moves to Cover Costly Cell Therapies
DJ
More sector news : Bio Therapeutic Drugs
Chart VERTEX PHARMACEUTICALS
Duration : Period :
Vertex Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VERTEX PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 211,23  $
Last Close Price 183,72  $
Spread / Highest target 27,9%
Spread / Average Target 15,0%
Spread / Lowest Target -0,39%
EPS Revisions
Managers
NameTitle
Jeffrey M. Leiden Chairman, President & Chief Executive Officer
Paul M. Silva Chief Financial Officer, Controller & Senior VP
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
Reshma Kewalramani Chief Medical Officer & Executive Vice President
Bruce I. Sachs Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
VERTEX PHARMACEUTICALS10.87%47 223
GILEAD SCIENCES1.42%80 344
REGENERON PHARMACEUTICALS-20.74%32 392
GENMAB28.01%13 210
NEUROCRINE BIOSCIENCES, INC.35.88%8 886
BEIGENE LTD--.--%8 765